by Jordana Choucair | Jan 9, 2023 | Life Sciences
Moderna Inc. said it pulled in $18.4 billion in COVID-19 vaccine sales last year, hitting its 2022 revenue forecast for the products. The company forecasted a minimum of $5 billion of sales this year. (Article here)
by Jordana Choucair | Jan 6, 2023 | Life Sciences
Moderna Inc. announced a $35 million licensing deal with CytomX Therapeutics for the development of certain investigational messenger RNA-based therapies. The deal offers CytomX access to Moderna’s mRNA technology, which has been used to develop COVID-19...
by Jordana Choucair | Jan 6, 2023 | Life Sciences
AstraZeneca PLC and Sanofi SA said the Food and Drug Administration (FDA) indicated it may expedite the review of the companies’ long-acting antibody for the prevention of infection caused by RSV, called nirsevimab, with action possibly coming in the third...
by Jordana Choucair | Jan 4, 2023 | Life Sciences
The Food and Drug Administration (FDA) announced it will allow pharmacies to dispense the abortion medication mifepristone to patients. The agency also said it would no longer enforce a rule requiring people to get the first of the two drugs in person at a clinic or...
by Jordana Choucair | Jan 4, 2023 | Life Sciences
Gilead Sciences Inc. and EVOQ Therapeutics Inc. are partnering to develop autoimmune disorder treatments in a deal worth up to $658.5 million. The companies will collaborate on preclinical work for rheumatoid arthritis and lupus treatments, and Gilead will then...
by Jordana Choucair | Jan 3, 2023 | Life Sciences
The House Oversight and Energy and Commerce committees released a report revealing that the Food and Drug Administration’s (FDA) approval for Alzheimer’s drug Aduhelm was “rife with irregularities.” According to the 18-month investigation, officials didn’t...
Recent Comments